Standard BioTools (LAB) Q1 2026 earnings review
Transformational Cash Infusion Meets Drastic Cost Reductions
Standard BioTools' Q1 2026 results reflect a company completely reinvented. With the $363M cash sale of SomaLogic to Illumina successfully closed, the company is now a leaner pure-play in mass cytometry and microfluidics sitting on an impressive ~$550M war chest. The base business grew 5% YoY to $21.1M, driven by a massive 35% surge in consumables that offset a 33% collapse in instrument sales. More importantly, aggressive restructuring slashed operating expenses by 37%, driving a 78% improvement in Adjusted EBITDA. Management is executing its playbook efficiently, setting a clear trajectory toward profitability exiting 2026.
🐂 Bull Case
The completion of the SomaLogic divestiture leaves LAB with ~$550M in liquidity (including a $25M post-Q1 earnout). This removes all funding risk and arms the company for inorganic growth in a buyer's market.
The Standard BioTools Business System (SBS) is proving highly effective. A 40% reduction in non-GAAP operating expenses led to a 78% reduction in EBITDA losses, validating management's path to positive EBITDA.
🐻 Bear Case
Instrument revenue plummeted 33% YoY to just $4.5M. Capital-constrained end markets are severely limiting large equipment purchases, pressuring future installed base expansion.
Despite Q1's 5% revenue growth, FY26 revenue guidance of $80M-$85M implies a slight contraction at the midpoint compared to FY25's $85M in continuing operations revenue.
⚖️ Verdict: 🟢
Bullish. The existential threat of cash burn is gone. Management has successfully amputated unprofitable segments, dramatically reduced costs, and generated enough cash to reshape the company through acquisitions. The base business is stabilizing.
Key Themes
Consumables Utilization Accelerating
Consumables revenue accelerated sharply, growing 35% YoY to $11.0M. Management attributed this to growth across all product categories, primarily led by microfluidics. This is a highly encouraging signal: even as labs pause new equipment purchases, they are actively utilizing their existing installed base, driving high-margin recurring revenue.
Capital Constraints Crush Instrument Sales (Macro)
The primary drag on the top line remains the capital equipment cycle. Instrument revenue fell 33% YoY to $4.5M, continuing a multi-quarter pattern of deceleration. Management cited 'capital-constrained end-markets' as the primary headwind. Without new instrument placements, future consumables growth will eventually face a ceiling.
Operating Leverage from SBS Restructuring
The Standard BioTools Business System (SBS) is delivering massive efficiency gains. Non-GAAP operating expenses collapsed by 40% YoY (from $25.6M to $15.3M). R&D was cut by more than half, and SG&A dropped significantly. This aggressive right-sizing is the primary reason the company is now forecasting positive Adjusted EBITDA exiting 2026.
The M&A Pivot
With the $363M net cash infusion from the SomaLogic sale to Illumina, Standard BioTools ended the quarter with $523.6M in liquid assets (plus a $25M earnout received in April). Management was explicit that they are 'fully focused on strategic capital deployment.' The company has transitioned from a turnaround story to an M&A platform story, seeking to acquire undervalued life science tools assets.
Other KPIs
Stable. GAAP gross margin declined slightly from 54.6% a year ago, while Non-GAAP gross margin ticked up from 57.1% to 57.7%. The shift was primarily driven by the changing product mix—higher consumables versus lower instruments—which naturally supports the non-GAAP margin profile.
This massive one-time influx reflects the closed sale of SomaLogic to Illumina, which generated a $172.3 million gain on the sale of the business. This completely alters the balance sheet and effectively funds the company's future M&A ambitions.
Guidance
Stable/Decelerating. Management reiterated this range. Compared to the FY25 continuing operations revenue of $85.0M, the midpoint of $82.5M implies a ~3% YoY decline. This suggests management expects the severe macro headwinds in instrument sales to persist and offset the growth in consumables.
Key Questions
Capital Deployment Strategy
With ~$550M in liquidity, what is the specific profile of the M&A targets you are evaluating? Are you looking for immediate accretion, or complementary technologies that can leverage the SBS operating model?
Sustainability of Consumables Growth
Consumables grew an impressive 35% this quarter. Was this driven by specific one-time stocking behaviors or large projects, or does this represent a structural increase in utilization rates across the microfluidics installed base?
Instrument Pipeline Visibility
Given the 33% decline in instrument sales, what are your leading indicators telling you about the timing of a capital expenditure recovery among academic and pharma customers?